Access Pharmaceuticals Announces the Commencement of a New AP5346 Clinical Study

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ask Centralassd	LSE:AKCA	London	Ordinary Share	GB0034031905	ORD 5P(ASSD CITY CENTRE REST SHS & CASH)

Share Name

Share Symbol

Market

Type

Share ISIN

Share Description

Ask Centralassd

LSE:AKCA

London

Ordinary Share

GB0034031905

ORD 5P(ASSD CITY CENTRE REST SHS & CASH)

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

Industry Sector

Turnover

Profit

EPS - Basic

PE Ratio

Market Cap

N/A

Access Pharmaceuticals Announces the Commencement of a New AP5346 Clinical Study

23/02/2006 3:37pm

PR Newswire (US)

Ask Centralassd (LSE:AKCA)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Ask Centralassd Charts.

DALLAS, Feb. 23 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Pink Sheets: AKCA) announced today the commencement of a new clinical study involving its DACH platinum polymer therapeutic, AP5346. The aim of the study, being conducted at the Moores Cancer Center at the University of California, San Diego in patients with head and neck cancer under a physician- sponsored IND, is to demonstrate the ability of the tumor-targeting polymer system to deliver more platinum to tumors than can be attained with oxaliplatin, the approved DACH platinum compound. David P. Nowotnik, Ph.D., Senior Vice President, Research and Development at Access, commented: "The effectiveness of platinum drugs is believed to increase as more platinum is delivered to the DNA of tumor cells. In preclinical studies, we have demonstrated that AP5346 delivers greater than 10-fold more platinum to the tumor DNA than is achieved by oxaliplatin. The clinical study is designed to provide us with valuable information on the effectiveness of our delivery system in man." This clinical study is the first to commence following the completion of a phase I study in Europe which demonstrated that AP5346 is well-tolerated, and that it is active as evidenced by the two partial responses and one stable disease among the 16 evaluable patients with far advanced disease in the trial. The results of that study were reported at the AACR-NCI-EORTC conference in Philadelphia in November. Access continues to manufacture AP5346 and activate clinical sites in Europe, and will participate in a phase II trial of the effectiveness and safety of AP5346 in patients with recurrent, platinum-sensitive ovarian cancer. Access Pharmaceuticals, Inc. is an emerging pharmaceutical company developing unique polymer linked cytotoxics for use in the treatment of cancer. Its lead product AP5346 is in Phase II clinical testing. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including but not limited to statements made relating to the manufacture and clinical development of our AP5346 product. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2004, Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 and other reports filed by us with the Securities and Exchange Commission. DATASOURCE: Access Pharmaceuticals, Inc. CONTACT: Stephen B. Thompson, Vice President & CFO of Access Pharmaceuticals, Inc., +1-214-905-5100; or investor relations, Donald C. Weinberger of Wolfe Axelrod Weinberger LLC, +1-212-370-4500, for Access Pharmaceuticals, Inc.

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AKCA Ask Centralassd